NCT02541227View on ClinicalTrials.gov

Cerebrolysin REGistry Study in Stroke

TerminatedOBSERVATIONAL
Enrollment

1,823

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2021

Conditions
Ischemic Stroke
Interventions
DRUG

Cerebrolysin

Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization

Trial Locations (1)

4024

AKH Linz, Linz

Sponsors
All Listed Sponsors
collaborator

SITS International

NETWORK

lead

Ever Neuro Pharma GmbH

INDUSTRY

NCT02541227 - Cerebrolysin REGistry Study in Stroke | Biotech Hunter | Biotech Hunter